Dr. Bryson joined Acerus from Cynapsus Therapeutics where he served as Chief Scientific Officer. He brings more than 20 years of experience in pharmaceutical development, having held scientific and executive management level positions at several pharmaceutical companies including Flamel Technologies SA, Bionisis SA, and Matregen Corporation. Dr. Bryson holds a BSc in Chemistry from Auburn University and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (“MIT”). He performed post-doctoral research under two well-esteemed chemists, the late Dr. J. Osborn at the University Louis Pasteur (Strasbourg, France) and Dr. D. Seyferth at MIT. Dr. Bryson joined Acerus from Cynapsus Therapeutics where he served as Chief Scientific Officer. He brings more than 20 years of experience in pharmaceutical development, having held scientific and executive management level positions at several pharmaceutical companies including Flamel Technologies SA, Bionisis SA, and Matregen Corporation. Dr. Bryson holds a BSc in Chemistry from Auburn University and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (“MIT”). He performed post-doctoral research under two well-esteemed chemists, the late Dr. J. Osborn at the University Louis Pasteur (Strasbourg, France) and Dr. D. Seyferth at MIT.

Reproductive Medicine, Pharmaceutical Products